We will rely on you to help lend your voice and support the biotechnology industry.
Get Involved
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
Learn More
See All
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
View
February 11 - 12, 2019 | New York, New York
Adelene Perkins has served as Infinity’s CEO and Chair since 2012, CEO and Board Member since 2009, President from 2008-2009 and EVP and CBO from 2002-2008. Previously, Ms. Perkins served as TransForm Pharmaceuticals’ VP of BD and helped build the company prior to its acquisition by J&J. From 1992-1999 she was at Genetics Institute (GI), now a unit of Pfizer, as VP of emerging businesses and formed and served as CEO of MetaMorphix, a joint venture between GI and Johns Hopkins University. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm. Ms. Perkins received her MBA from Harvard Business School and her BS in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is vice chairman of the Board of Project Hope.
This speaker's sessions: